Side-by-side · Research reference
GHK-CuvsHGH Fragment 176-191
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED8/47 cited
BAnimal-StrongHUMAN-REVIEWED28/59 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
01Mechanism of Action
Parameter
GHK-Cu
HGH Fragment 176-191
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Feedback intact?
Replaces declining endogenous levels
N/A — does not interact with GH/IGF-1 axis
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Antibody development
—
Not reported in available studies
02Dosage Protocols
Parameter
GHK-Cu
HGH Fragment 176-191
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
Once daily (animal models)
Lower / starter dose
0.5 mg / day SQ
—
Duration
8–12 weeks for visible skin / hair effect
—
Reconstitution
Bacteriostatic water; light-protected
—
Timing
No specific time; evening preferred for topicals
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Animal dose (IP)
—
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
Human equivalent dose
—
Not established — no published human RCTs
Detection window
—
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
Oral bioavailability
—
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
03Metabolic / Fat Loss Evidence
Parameter
GHK-Cu
HGH Fragment 176-191
Weight gain reduction
—
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
Body fat reduction
—
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
Lipolytic activity
—
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
Insulin sensitivity
—
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
IGF-1 impact
—
No elevation — fragment does not activate GH/IGF-1 axis
Beta-3 AR dependency
—
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
Human evidence
—
None published — pre-clinical only
04Side Effects & Safety
Parameter
GHK-Cu
HGH Fragment 176-191
Injection site reaction
Erythema, mild pruritus (common)
—
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
—
Wilson disease
Contraindicated
—
Human safety data
—
Not available — no published human trials
Metabolic profile
—
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
05Administration Protocol
Parameter
GHK-Cu
HGH Fragment 176-191
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Animal protocols: 14–19 days. Human duration not established — no published trials.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
HGH Fragment 176-191
— no documented stacks